Table 3. Percentage of cases with various PD-L1 expression on tumor cells visualized by immunohistochemistry method, using 22C3 monoclonal antibody in patients with different clinical characteristics.

Clinical characteristic	<1 % TPS	≥1 % TPS	<5% TPS	≥5% TPS	<50% TPS	≥50% TPS
Male, n(%)	9 (36)	16 (64)	10 (40)	15 (60)	14 (56)	11 (44)
Female, n(%)	4 (17.4)	19 (82.6)	6 (26.1)	17 (73.9)	12 (52.2)	11 (47.8)
Chi-square:	2.101		1.043		0.071
p-value:	0.1472		0.3071		0.79
<67 years old, n(%)	8 (30.8)	18 (69.2)	10 (38.5)	16 (61.5)	16 (61.5)	10 (38.5)
≥67 years old, n(%)	5 (22.7)	17 (77.3)	6 (27.3)	16 (82.7)	10 (45.4)	12 (54.6)
Chi-square:	0.39		0.671		1.242
p-value:	0.5323		0.4127		0.2651
Smokers, n(%)	8 (21)	30 (79)	10 (26.3)	28 (73.7)	19 (50)	19 (50)
Non-smokers, n(%)	5 (50)	5 (50)	6 (60)	4 (40)	7 (70)	3 (30)
Chi-square:	3.359		4.042		1.276
p-value:	0.0668		0.0444		0.2586
SCC, n(%)	1 (7.1)	13 (92.9)	2 (14.3)	12 (85.7)	4 (28.6)	10 (71.4)
Non-SCC, n(%)	12 (35.3)	22 (64.7)	14 (41.2)	20 (58.8)	22 (64.7)	12 (35.3)
Chi-square:	3.98		3.227		5.215
p-value:	0.0460		0.0724		0.0224
Early stages (I-IIIA), n(%)	7 (20.6)	27 (79.4)	9 (26.5)	25 (73.5)	19 (55.9)	15 (44.1)
Advanced stages (IIIB-IV), n(%)	6 (42.9)	8 (57.1)	7 (50)	7 (50)	7 (50)	7 (50)
Chi-square:	2.49		2.471		0.138
p-value:	0.1146		0.116		0.7103
FFPE tissue, n(%)	10 (23.3)	33 (76.7)	13 (30.2)	30 (79.8)	23 (53.5)	20 (46.5)
Cellblock, n(%)	3 (60)	2 (40)	3 (60)	2 (40)	3 (60)	2 (40)
Chi-square:	3.062		1.786		0.077
p-value:	0.08		0.1814		0.7814
EGFR wt, n(%)	10 (24.4)	31 (75.6)	13 (31.7)	28 (68.3)	22 (53.7)	19 (46.3)
EGFR mut, n(%)	3 (42.9)	4 (57.1)	3 (42.9)	4 (57.1)	4 (57.1)	3 (42.9)
Chi-square:	1.033		0.334		0.029
p-value:	0.3095		0.5633		0.8648
ALK rearrangement, n(%)	3 (100)	0 (25)	3 (100)	0 (100)	3 (100)	0 (100)
No ALK rearrangement, n(%)	10 (22.7)	34 (77.3)	13 (29.5)	31 (70.5)	23 (52.3)	21 (47.7)
Chi-square:	8.381		6.209		2.588
p-value:	0.0038		0.0127		0.1077